HFpEF is a relatively complicated and fatal clinical syndrome with high mortality and morbidity. SGLT2 inhibitors are found to be promising medications in recent years although experiments are still enduring to find evidence of their effects on HFpEF. Indeed, incidences of hospitalization, myocardial infarction, cardiovascular death, all-cause mortality, and quality of life are shown to be improved after SGLT2 inhibitors treatment in both diabetic and non-diabetic patients.